All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @ahmadyasinmd on TikTok · 83s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @ahmadyasinmd's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00This peptide may help prepare your damaged or injured tissues. This is TB-500 or thymosin beta.
  2. 0:07This is Dr. Jassen, I talk peptides, bio-regulators and serums. Today I'm going to talk about TB-500,
  3. 0:13which is a promising peptide in the field of repair of injured tissues. It helps cells migrate
  4. 0:19to the side of injury, speed up recovery and enhance new blood vessel formation to the damaged
  5. 0:26areas. This peptide may accelerate tendon, ligaments and muscle healing, may limit cutting during
  6. 0:33healing and may promote hair growth. The common side effects are redness and rotation at the
  7. 0:39side of injection. Sometimes it may cause allergic reaction. It's called the histamine response.
  8. 0:46So if you have allergies, be careful. I do recommend to stack it with BPC-157 for better outcome and
  9. 0:54even better if you do that with BPC-157 and copper peptide that will help you to glow more.
  10. 1:00This video is for educational purposes only. Do not attempt or buy peptides without talking to your doctor.
  11. 1:06Typical dosing is 2 milligrams daily for eight weeks on and six weeks off. Usually taken at the
  12. 1:14if you want to know more about the peptide world, please like the video and follow me and I'll see you in
  13. 1:18the next one. Thank you so much for watching.

@ahmadyasinmd's TB-500 claims need more evidence

Ahmad Yasin MD

TikTok creator

7.1K viewsWatch on TikTok

Quick answer

TB-500 is a synthetic fragment of thymosin beta-4 (residues 17-23) with preclinical evidence supporting roles in cell migration, angiogenesis, and tissue repair, primarily from animal models. It is not FDA-approved for human therapeutic use, has no established human dosing protocol from clinical trials, and is subject to evolving compounding pharmacy regulations in the United States. Patients interested in peptide therapy should consult a licensed provider who can discuss current regulatory status and individual risk factors before any use.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

Peptide social video fact-checksTB-500 (Thymosin Beta-4)Provider discussion

Evidence signal

Source-backed review

Regulatory reality

TB-500 (Thymosin Beta-4) access requires the right clinical path

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 6 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For @ahmadyasinmd's TB-500 claims need more evidence, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

TB-500 (Thymosin Beta-4) is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Claim path

Keep researching this tb-500 video claims cluster

Best for searchers comparing TB-500 recovery claims with BPC-157 and broader peptide-safety context.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "@ahmadyasinmd's TB-500 claims need more evidence" from Ahmad Yasin MD. We read the clip as a Peptide social video fact-checks claim about TB-500 (Thymosin Beta-4), then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: TB-500 is a synthetic fragment of thymosin beta-4 (residues 17-23) with preclinical evidence supporting roles in cell migration, angiogenesis, and tissue repair, primarily from animal models.

The reason this review is not generic is the source wording and the canonical claim label "peptides what is tb 500 tb 500 thymosin beta 4 fragment 17 23 i." In this clip, the useful excerpt is: "This peptide may help prepare your damaged or injured tissues." That wording changes the review because it points to TB-500 (Thymosin Beta-4) safety, access, evidence, and fit, not a one-size-fits-all protocol.

The source trail for this page is checked against Multifunctionality and Possible Medical Application of the BPC 157 Peptide (2025), Gastric pentadecapeptide BPC 157 and its role in accelerating musculoskeletal soft tissue healing (2019), and Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review (2025), plus the creator's own wording. TB-500 (Thymosin Beta-4) still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

No FDA-approved human dose for TB-500 exists.
People who land here are usually trying to understand whether the TB-500 (Thymosin Beta-4) claim is evidence-backed, safe, and relevant to their own situation.
The strongest next step is to compare the claim with FormBlends' TB-500 (Thymosin Beta-4) guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

TB-500 is a synthetic fragment of thymosin beta-4 (residues 17-23) with preclinical evidence supporting roles in cell migration, angiogenesis, and tissue repair, primarily from animal models.

FormBlends verdict

TB-500 (Thymosin Beta-4) safety, access, evidence, and fit

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with the TB-500 (Thymosin Beta-4) guide, safety notes, access rules, and a licensed-provider review.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • TB-500 is a synthetic fragment of thymosin beta-4 (residues 17-23) with preclinical evidence supporting roles in cell migration, angiogenesis, and tissue repair, primarily from animal models. It is not FDA-approved for human therapeutic use, has no established human dosing protocol from clinical trials, and is subject to evolving compounding pharmacy regulations in the United States. Patients interested in peptide therapy should consult a licensed provider who can discuss current regulatory status and individual risk factors before any use.
  • TB-500 is a synthetic fragment of thymosin beta-4 (amino acids 17-23) with preclinical, not clinical, evidence for tissue repair and angiogenesis.
  • No FDA-approved human dose for TB-500 exists. The '2 mg daily for 8 weeks' figure in this video is not derived from published human clinical trials.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • TB-500 (Thymosin Beta-4) decisions still need source quality, legal access, and provider oversight checks.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against the TB-500 (Thymosin Beta-4) guide, cost path, safety notes, and provider review before acting.

Review TB-500 (Thymosin Beta-4)

What You'll Learn

  • TB-500 is a synthetic fragment of thymosin beta-4 (amino acids 17-23) with preclinical, not clinical, evidence for tissue repair and angiogenesis.
  • No FDA-approved human dose for TB-500 exists. The '2 mg daily for 8 weeks' figure in this video is not derived from published human clinical trials.
  • A 2010 review by Goldstein and Kleinman (Annals of the New York Academy of Sciences) supports TB4's wound healing mechanisms in animal models, but human RCT data is absent.
  • TB-500 is not FDA-approved for human therapeutic use. Compounding pharmacy access has become more restricted following increased FDA scrutiny of peptides beginning in 2023.
  • The histamine response warning the creator gave is accurate. Mast cell activation and local injection reactions have been reported in users of thymosin-based peptides.
  • Hair growth claims for TB-500 rest on a single 2004 mouse study. This is not a validated human use and should not be a primary reason anyone seeks this peptide.
  • Stacking multiple unregulated peptides like TB-500, BPC-157, and copper peptide has no human safety data. Presenting this as routine optimization advice overstates what is known.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @ahmadyasinmd actually say?

The creator, identifying as Dr. Jassen, describes TB-500 as a peptide that "helps cells migrate to the side of injury, speed up recovery and enhance new blood vessel formation." He lists potential benefits including tendon, ligament, and muscle healing, reduced scarring, and hair growth. He recommends stacking it with BPC-157 and copper peptide, and gives a specific dosing protocol of "2 milligrams daily for eight weeks on and six weeks off." He ends with a disclaimer that this is educational content and to consult a doctor before purchasing peptides.

To his credit, he hedged most claims with "may" and included a side effect warning about histamine responses. But the dosing recommendation and stack advice are more concrete than the evidence base warrants, and that's where things get complicated.

Does the science back this up?

Partially, but mostly in animals and in vitro. The evidence for TB-500 in humans is thin. Most of what we know comes from preclinical work, and the leap from mouse tendon to your shoulder is not a small one.

Thymosin beta-4 (TB4), the parent protein, has legitimate research behind it. It promotes actin polymerization, cell migration, and angiogenesis, which is new blood vessel formation. A 2010 review by Goldstein and Kleinman in the Annals of the New York Academy of Sciences confirmed TB4's role in wound healing and tissue repair in animal models. The fragment TB-500, corresponding to residues 17-23 of TB4, appears to retain some of these bioactive properties. A 2010 study by Philp et al. in the Journal of Applied Physiology showed improved cardiac repair in animal models. However, no large-scale randomized controlled trials in humans have confirmed these effects for musculoskeletal injury. The angiogenesis claim is reasonably supported in preclinical literature. The hair growth claim is based on a single 2004 study by Philp et al. in the Journal of Investigative Dermatology showing TB4 promoted hair follicle stem cell migration in mice. That's a long way from a clinical recommendation.

What did they get wrong, and what did they get right?

The creator got the mechanism broadly right. Cell migration, angiogenesis, and tissue repair are legitimate areas of TB4 and TB-500 research. The histamine response warning is accurate and worth noting.

But there are real problems here. First, the dosing. Giving a specific protocol of "2 milligrams daily for eight weeks" is not supported by any published human clinical trial. There is no established therapeutic dose for TB-500 in humans because it has not been approved by the FDA for human use. Presenting this as a standard regimen is misleading regardless of how many clinics use it off-label.

Second, the stack recommendation. Telling viewers to combine TB-500 with BPC-157 and copper peptide for "better outcome" and to "glow more" conflates speculative synergy with evidence. BPC-157 has its own preclinical data, but stacking multiple unregulated peptides without human safety data is not something a responsible medical communicator should present as routine optimization advice.

Third, the phrase "limit cutting during healing" appears to be a garbled reference to reducing fibrosis or scarring. That claim has some preclinical support, but the way it was stated is vague enough to be confusing to a general audience.

What should you actually know?

TB-500 is not FDA-approved for human use. It exists in a gray zone where compounding pharmacies have supplied it, but regulatory pressure on peptide compounding has increased significantly since 2023. The FDA's position on many of these peptides has shifted, and access is not guaranteed or stable.

The preclinical data is genuinely interesting. Researchers are studying TB4 and its fragments for cardiac repair, wound healing, and neurological recovery. That research is real. But interesting preclinical data does not equal a validated human therapy, and the gap between the two is where most peptide marketing quietly lives.

If you are considering TB-500 for an injury, the honest answer is that no one can tell you with confidence what dose works, what the long-term safety profile looks like in humans, or whether the benefits you read about will translate to your specific situation. That uncertainty should be front and center in any video about this compound, and it largely was not here.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Ahmad Yasin MD · TikTok creator

7.1K views on this video

🧬 What is TB-500? TB-500 (Thymosin Beta-4 Fragment 17–23) is a short segment of the Thymosin Beta-4 protein that may support tissue repair and cell migration. Research suggests it may help guide cell

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about tb-500?

TB-500 is a synthetic fragment of thymosin beta-4 (amino acids 17-23) with preclinical, not clinical, evidence for tissue repair and angiogenesis.

What does the video say about no fda-approved human dose for tb-500 exists. the '2 mg?

No FDA-approved human dose for TB-500 exists. The '2 mg daily for 8 weeks' figure in this video is not derived from published human clinical trials.

What does the video say about a 2010 review by goldstein?

A 2010 review by Goldstein and Kleinman (Annals of the New York Academy of Sciences) supports TB4's wound healing mechanisms in animal models, but human RCT data is absent.

What does the video say about tb-500?

TB-500 is not FDA-approved for human therapeutic use. Compounding pharmacy access has become more restricted following increased FDA scrutiny of peptides beginning in 2023.

What does the video say about the histamine response warning the creator gave?

The histamine response warning the creator gave is accurate. Mast cell activation and local injection reactions have been reported in users of thymosin-based peptides.

What does the video say about hair growth claims for tb-500 rest on a single 2004?

Hair growth claims for TB-500 rest on a single 2004 mouse study. This is not a validated human use and should not be a primary reason anyone seeks this peptide.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by Ahmad Yasin MD, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.